As IDH inhibitors show different inhibitory effects on different mutation isoforms (amino acid substitution at arginine residue),16, 20, 28 we then sought to compare IDH active‐site mutation isoforms in NSCLC with those in glioma and AML. The gene discussed is IDH1; the disease is central nervous system cancer.